In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...
In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...
A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.
6d
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
Madrigal’s Rezdiffra has launched a new MASH market, but ‘tremendous change’ is on the horizon
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback